Lung Cancer Diagnostics Market Report by Diagnosis Test Type, Cancer Type, EndUsers, Country and Companies Analysis 2026-2034

Lung Cancer Diagnostics Market Size and Forecast 2026-2034

Lung Cancer Diagnostics Market is set to rise from US$ 13.2 Billion in 2025 to US$ 27.4 Billion in 2034, registering a Compound Annual Growth Rate (CAGR) of 7.21% from 2026-2034. This is due to the rising incidence of lung cancer, the growing need for early detection, and the development of diagnostic tools. The increasing number of screening programs, the adoption of personalized medicine, and the improvement of the healthcare infrastructure are also contributing factors.

Lung Cancer Diagnostics Market Overview

Lung cancer diagnostics is the set of medical procedures and tests that are used to diagnose, identify, and monitor lung cancer. The diagnostic tests and procedures are used to identify lung cancer at an early stage and determine the type of cancer, which helps in making the right treatment decisions. The most common diagnostic tests and procedures include imaging tests such as chest X-rays, computed tomography scans, positron emission tomography scans, and magnetic resonance imaging. Biopsy tests, molecular diagnostics, and sputum cytology tests are also used to confirm the presence of cancer and identify genetic mutations that affect treatment choices. Liquid biopsy and next-generation sequencing are also emerging as advanced diagnostic technologies.

The demand for lung cancer diagnostics is rising globally due to the increasing number of lung cancer cases, especially among smokers and the elderly. Early-stage diagnosis of lung cancer has been shown to improve survival rates and treatment outcomes. Governments and healthcare institutions are also encouraging lung cancer screening programs to help diagnose lung cancer at an early stage. Advances in technology, increased awareness about preventive healthcare, and the adoption of personalized medicine are also fueling the demand for accurate and efficient lung cancer diagnostic solutions globally.

Growth Drivers of the Lung Cancer Diagnostics Market

Rising Global Prevalence of Lung Cancer and Smoking-Related Diseases

There is a rising incidence of lung cancer in India, with projected cases rising from 63,708 (2015) to 81,219 (2025). The rising incidence can be attributed to smoking (India has close to 100 million adult smokers) and pollution. The majority of patients are diagnosed with advanced disease (80-85% of patients have incurable disease), resulting in approximately 60,000 deaths per annum due to lung cancer. The rising incidence of lung cancer globally is one of the main drivers for the lung cancer diagnostics market. Lung cancer is one of the leading causes of cancer-related deaths, mainly due to smoking, air pollution, occupational exposure, and lifestyle factors. There has also been a rise in the risk of lung cancer among non-smokers due to increased exposure to environmental pollutants and secondhand smoke. The rising incidence of lung cancer has led to a significant rise in the demand for early and accurate diagnostic solutions. Early diagnosis translates to higher survival rates and hence the impetus for healthcare professionals to adopt modern diagnostic tools. Governments and healthcare institutions are encouraging screening programs, particularly among high-risk groups such as smokers and the elderly. Greater awareness about the need for early diagnosis and preventive healthcare is also encouraging people to undergo screening. The growing prevalence of lung cancer is expected to fuel the demand for lung cancer diagnostic products.

Technological Advancements in Diagnostic Techniques

Ongoing technological developments in diagnostic tools are contributing greatly to the accuracy and efficiency of lung cancer diagnosis. Advanced imaging technologies like low-dose computed tomography (LDCT), positron emission tomography (PET), and high-resolution imaging allow for the early detection of lung abnormalities. Moreover, molecular diagnostics, liquid biopsies, and genetic testing assist in the identification of unique cancer mutations, making it possible to develop targeted treatment strategies. These advanced diagnostic technologies are less invasive, quicker, and more accurate than conventional diagnostic tools. Artificial intelligence and digital imaging technologies are also enhancing the accuracy of lung cancer diagnosis by assisting doctors in the early detection of cancer. Automation and advancements in laboratory testing have minimized the time required for testing and increased accuracy. Healthcare professionals are increasingly embracing these innovative diagnostic technologies to improve patient outcomes. With advancements in technology, the emergence of more efficient, accurate, and cost-effective diagnostic technologies is anticipated to fuel robust growth in the lung cancer diagnostics market. May 2025: Johnson & Johnson MedTech, a world leader in surgical technologies and solutions, hasinducted Qure.ai, a world leader in AI for healthcare, as a strategic partner with Johnson & JohnsonPrivate Limited, a Johnson & Johnson company, to improve early detection of lung cancer in India. This partnership combines the best of AI and medical technology to detect lung cancer at its most treatable stage.

Growing Adoption of Early Screening Programs and Preventive Healthcare

The rising trend of early detection and preventive healthcare is a major driver for the lung cancer diagnostics market. Various nations have launched a nationwide screening program to detect lung cancer at an early stage, especially in high-risk groups such as smokers and older people. Early screening enables the detection of cancer before the onset of symptoms, which increases the chances of successful treatment and survival rates. Various healthcare institutions are spreading awareness about the importance of regular screening and early detection. Furthermore, the trend of preventive healthcare is encouraging people to undergo regular health screenings, including lung cancer screening. Healthcare professionals are also increasingly recommending the use of advanced imaging and molecular diagnostics for early detection. As awareness, accessibility, and screening participation continue to rise, the demand for lung cancer diagnostic technologies is likely to rise substantially. Sept 2023, The National Lung Cancer Early Detection Program in Taiwan was able to identify 85 percent of lung cancer patients at either phase 0 or phase 1, proving that lung cancer screening can identify lung cancer at an early enough stage to allow doctors to intervene.

Challenges of the Lung Cancer Diagnostics Market

High Cost of Advanced Diagnostic Technologies

One of the challenges that can affect the growth of the market for advanced lung cancer diagnostic technology is its high cost. Imaging devices like CT scanners, PET scanners, and molecular diagnostic devices are costly to purchase and maintain. Diagnostic tests like imaging studies, biopsies, and genetic analyses can also be expensive for patients, especially in areas where insurance coverage is limited. The high cost of advanced lung cancer diagnostic technology may affect access to early diagnosis, especially in developing countries. Small healthcare facilities may not be able to afford the cost of advanced diagnostic technology. In addition, maintenance costs, qualified personnel, and infrastructure costs will also be high. The high cost of advanced lung cancer diagnostic technology may affect patient outcomes due to delays in diagnosis and treatment. Overcoming the cost challenge through technological advancement, improved funding of healthcare, and increased insurance coverage will be important to ensure access to lung cancer diagnostics worldwide.

Limited Access to Diagnostic Services in Developing Regions

Another significant challenge in the lung cancer diagnostics market is the limited availability of advanced healthcare infrastructure and diagnostic facilities. This is because many emerging nations have inadequate imaging facilities, diagnostic labs, and specialized healthcare professionals to conduct complex diagnostic procedures. In addition, the lack of awareness about the symptoms and screening programs for lung cancer further hampers the early diagnosis of the disease. Patients in these countries often consult healthcare professionals only when the disease has progressed to an advanced stage, making treatment less effective. Moreover, limited government support and funding in the healthcare sector can also impede the development of diagnostic facilities. The lack of skilled radiologists, pathologists, and technical staff can also impact the efficiency of diagnostic procedures. Enhancing healthcare infrastructure, investments in diagnostic technology, and training programs for healthcare professionals will be critical to overcome these hurdles and fuel market growth.

Lung Cancer Biopsy Diagnostics Market

Lung cancer biopsy diagnostics are of utmost importance in the diagnosis of cancer by analyzing the samples obtained from the lungs. The different types of biopsies, such as needle biopsy, bronchoscopy biopsy, and surgical biopsy, are performed based on the location of the tumor and the health of the patient. The rising incidence of lung cancer and the need for accurate diagnosis are fueling the demand for biopsies. Biopsy diagnostics are also used to analyze the properties of cancer, which helps in the development of targeted treatments. Advances in technology have made biopsies more accurate, safe, and efficient, with fewer complications and faster recovery times. Healthcare professionals use biopsy diagnostics to ensure accurate diagnosis and treatment. With the rising need for early diagnosis and personalized medicine, the demand for lung cancer biopsy diagnostics is anticipated to rise substantially.

Lung Cancer Molecular Test Diagnostics Market

Lung cancer molecular test diagnostics are based on the detection of particular genetic mutations and markers linked to cancer. Molecular tests for lung cancer help in determining the most appropriate treatment strategies by identifying mutations like EGFR, ALK, and other genetic mutations. Molecular testing has helped in the development of personalized medicine, which enables doctors to choose targeted therapies that enhance treatment efficacy and minimize side effects. The rising trend of precision medicine is one of the major factors propelling the growth of molecular diagnostics. Molecular tests can be carried out through tissue biopsies or liquid biopsies, which are less invasive. Advances in technology have enhanced the speed, sensitivity, and availability of molecular testing. The pharmaceutical industry also uses molecular diagnostics for the development of drugs. Healthcare professionals are increasingly recommending molecular testing for making treatment decisions and enhancing patient outcomes. With the growing trend of personalized cancer treatment, the market for lung cancer molecular test diagnostics is anticipated to grow steadily.

Small Cell Lung Cancer Diagnostics Market

Small Cell Lung Cancer (SCLC) is a highly aggressive type of lung cancer that progresses and metastasizes quickly, and hence, early and accurate diagnosis is essential. The diagnostic tests for SCLC include imaging tests, biopsy procedures, and molecular testing for cancer type and stage confirmation. Early diagnosis enables healthcare professionals to start treatment promptly, which helps to improve survival rates and outcomes. The growing prevalence of lung cancer, especially among smokers and high-risk groups, is driving the demand for effective diagnostic solutions. Healthcare professionals are resorting to advanced imaging modalities and lab tests to enhance diagnostic accuracy. Rising awareness about early cancer detection and increasing screening programs are also contributing to market growth. Advances in research and technology are enhancing diagnostic abilities and enabling faster detection. With the focus on early diagnosis and effective disease management in the healthcare industry, the demand for small cell lung cancer diagnostic solutions is likely to rise.

Lung Cancer Diagnostic Imaging Centers Market

Diagnostic imaging centers are playing a significant role in the diagnosis of lung cancer through advanced imaging technology such as CT scans, PET scans, X-rays, and MRI scans. The demand for imaging services has increased due to awareness about the early detection of cancer and the rise in screening programs. Imaging centers are providing faster and easier diagnostic services compared to traditional hospital settings. Advances in imaging technology have improved the efficiency of diagnosis. The rising number of high-risk patients, including smokers and the elderly, is fueling the demand for regular lung cancer screening. Imaging centers are also used for monitoring treatment and disease progression. Healthcare organizations are using these centers for accurate and efficient diagnosis. With the expansion of lung cancer screening programs and advances in technology, imaging centers will continue to be an important part of lung cancer diagnosis.

Lung Cancer Hospital Associated Labs Market

Hospital-associated laboratories play a crucial role in carrying out different diagnostic tests needed for the detection and management of lung cancer. The laboratories are involved in biopsy analysis, molecular testing, and pathology studies to confirm cancer diagnosis and determine the type and stage of cancer. Hospital laboratories offer comprehensive diagnostic services, allowing for quick communication between healthcare providers and laboratory professionals. The rising number of hospital admissions for cancer diagnosis and treatment is fueling the demand for laboratory testing services. Modern laboratory technology has enhanced the accuracy, speed, and turnaround time of laboratory tests. Hospital laboratories are also contributing to personalized medicine through genetic and molecular testing for targeted therapy. The availability of qualified personnel and advanced diagnostic facilities ensures the accuracy of results. With the expansion of cancer treatment services and the adoption of modern diagnostic technology in hospitals, hospital-associated laboratories will continue to play a significant role in lung cancer diagnosis and management globally.

United States Lung Cancer Diagnostics Market

The United States lung cancer diagnostics market is well-established owing to its robust healthcare infrastructure and focus on early cancer diagnosis. The high incidence of lung cancer, especially among smokers and the elderly, is fueling the demand for accurate and timely diagnostic tools. Advanced imaging modalities like CT scans, PET scans, and molecular diagnostics are widely adopted in the healthcare sector for lung cancer diagnosis and monitoring. National screening programs and preventive healthcare measures encourage high-risk groups to undergo regular screenings. The presence of top biotech firms and diagnostic labs in the United States is fueling innovation in diagnostic technologies. Moreover, the rising adoption of personalized medicine and targeted therapies is fueling the demand for molecular diagnostics. The United States' focus on early diagnosis and precision medicine will drive the lung cancer diagnostics market to grow substantially in the coming years. In July 2025, the U.S. FDA approved the Oncomine Dx Express Test, an NGS-based companion diagnostic, for the detection of EGFR exon 20 insertion mutations in NSCLC patients eligible for sunvozertinib (Zegfrovy) treatment. This is a major step forward in the rapid genomic characterization of a hard-to-target NSCLC subtype, with results available in less than 24 hours.

United Kingdom Lung Cancer Diagnostics Market

The United Kingdom lung cancer diagnostics market is growing steadily due to government-supported healthcare programs and increasing awareness of early cancer detection. The public healthcare system plays a key role in providing access to diagnostic services, including imaging and laboratory testing. The rising incidence of lung cancer and increasing aging population are major factors driving demand for diagnostic solutions. National screening programs and awareness campaigns promote early diagnosis, leading to improved treatment outcomes and survival rates. Healthcare providers are adopting advanced imaging solutions and molecular diagnostics to enhance diagnostic accuracy. The presence of leading research institutions and diagnostic laboratories supports innovation and development of new diagnostic solutions. Jan 2026, Optellum, a world leader in AI-enabled lung cancer risk assessment, is delighted to announce its selection in a groundbreaking NHS initiative that integrates Optellum's AI-driven lung cancer risk stratification with robotic-assisted bronchoscopy in a single, end-to-end diagnostic solution for lung cancer. This initiative is led by Guy's and St Thomas' NHS Foundation Trust and aims to support healthcare professionals in diagnosing lung cancer earlier, more accurately, and with fewer invasive procedures.

India Lung Cancer Diagnostics Market

The Indian lung cancer diagnostics market is growing at a fast pace due to the development of the country's healthcare infrastructure and growing awareness among people about cancer diagnosis. The rising incidence of lung cancer, caused by smoking, air pollution, and occupational hazards, is generating significant demand for diagnostic services. Hospitals, diagnostic centers, and imaging facilities are increasingly adopting modern diagnostic technologies like CT scans and molecular diagnostics. Government efforts to enhance cancer care and extend the reach of healthcare are also driving the market. In addition, the rising number of private diagnostic facilities is enhancing access to modern diagnostic facilities. Growing awareness about early detection and preventive healthcare is encouraging more people to get screened. Nov 2025, Yashoda Hospital, Hitech City, in association with Qure.ai and AstraZeneca, has launched an AI-powered Lung Nodule Clinic to facilitate early detection and timely management of lung cancer and other respiratory disorders.

Saudi Arabia Lung Cancer Diagnostics Market

The Saudi Arabian market for lung cancer diagnostics is growing due to increased investment in healthcare infrastructure and advanced medical technology. The increasing incidence of lung cancer and awareness of the need for early diagnosis are driving the demand for diagnostic services. Healthcare providers are adopting advanced imaging and molecular diagnostics to enhance diagnostic accuracy and patient outcomes. The government's efforts to modernize the healthcare sector and enhance cancer care services are contributing to market growth. The expansion of hospitals, diagnostic centers, and cancer care facilities is enhancing access to advanced diagnostic solutions. Jan 2026 - ImmunityBio, Inc., a commercial-stage immunotherapy company, today announced that the Saudi Food and Drug Authority (SFDA) has granted accelerated approval of ANKTIVA(R) (nogapendekin alfa inbakicept) in combination with immune checkpoint inhibitors for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed following standard-of-care therapy. This is the first approval of the Company's innovative therapy for this indication anywhere in the world, and the first approval for subcutaneous administration.

Market Segments

Diagnosis Test Type

• Imaging Test
• Biopsy
• Sputum Cytology
• Molecular Test
• Others

Cancer Type

• Non- Small Cell Lung Cancer
• Small Cell Lung Cancer

End-User

• Hospital Associated Labs
• Independent Diagnostic Laboratories
• Diagnostic Imaging Centers
• Cancer Research Institutes
• Others

Countries- Industry is divided into 25 viewpoints:

North America

• United States
• Canada

Europe

• France
• Germany
• Italy
• Spain
• United Kingdom
• Belgium
• Netherlands
• Turkey

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Thailand
• Malaysia
• Indonesia
• New Zealand

Latin America

• Brazil
• Mexico
• Argentina

Middle East & Africa

• South Africa
• Saudi Arabia
• United Arab Emirates

All the Key players have been covered from 5 Viewpoints:

• Overviews
• Key Person
• Recent Developments
• SWOT Analysis
• Revenue Analysis

Company Analysis:

• llumina
• Abbott Laboratories
• Thermo Fisher Scientific, Inc.
• QIAGEN N.V.
• Roche Holding AG.
• Sanofi S.A.
• Agilent Technologies
• bioMerieux